FDA-Approved Fedratinib Identified as Key Driver for Enhanced Communication Between Vital Cellular Powerhouses

University of Michigan researchers find that the drug fedratinib promotes ERMCS formation. Read how this discovery could impact neurodegeneration and obesity.

By: AXL Media

Published: Mar 14, 2026, 11:04 AM EDT

Source: Information for this report was sourced from Michigan Medicine - University of Michigan

Decoding the Urban Infrastructure of the Human Cell

The internal architecture of a human cell operates much like a modern city, where specialized organelles perform distinct infrastructural roles. Mitochondria function as the primary powerhouses, the endoplasmic reticulum serves as a complex transport hub, and lysosomes manage waste disposal. For a cell to maintain a healthy metabolism, these various "districts" must communicate effectively. This inter-organelle dialogue occurs at membrane contact sites, specifically the junctions where the endoplasmic reticulum and mitochondria meet, known as ERMCS.

Consequences of Disrupted Cellular Communication

When the organization of these contact sites is dysregulated, the resulting breakdown in communication can lead to a wide spectrum of severe pathologies. Researchers have linked ERMCS dysfunction to the onset of neurodegeneration, obesity, cancer, and diabetes. Despite the clear clinical significance of these junctions, the biological drivers that organize and sustain them have remained largely mysterious. A new study from the University of Michigan has now identified a pharmacological pathway that can actively induce the formation of these vital contact sites.

Pharmacological Screening and the Discovery of Fedratinib

To identify potential therapeutic leads, the research team screened a comprehensive library of FDA-approved drugs using both human and mouse cell lines. The screening process identified fedratinib—a drug currently approved for the treatment of certain cancers—as a potent influencer of ERMCS formation. Notably, the researchers observed that the increase in contact sites was reversible, subsiding once the drug was removed from the cellular environment. This suggests that fedratinib can be used as a precise tool to modulate cellular connectivity.